Christiaan M. Roosendaal
Doetinchem, GE, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Treatment satisfaction during personalized extended interval dosing of natalizumab in patients with multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: April 30, 2026
Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab.
Journal: European journal of neurology
Published: March 19, 2026
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: December 31, 2024
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: November 04, 2024
Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.
Journal: Journal of the neurological sciences
Published: March 15, 2024
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: June 29, 2023
Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: September 27, 2022
Electrophysiologic testing aids diagnosis and subtyping of myoclonus.
Journal: Neurology
Published: June 23, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026